

RESEARCH

Open Access



# Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders

Rachel M. Rahn<sup>1,2,3</sup>, Claire T. Weichselbaum<sup>1,2,4</sup>, David H. Gutmann<sup>4,5</sup>, Joseph D. Dougherty<sup>1,2,4†</sup> and Susan E. Maloney<sup>2,4\*†</sup> 

## Abstract

**Background:** Motor deficits such as abnormal gait are an underappreciated yet characteristic phenotype of many neurodevelopmental disorders (NDDs), including Williams Syndrome (WS) and Neurofibromatosis Type 1 (NF1). Compared to cognitive phenotypes, gait phenotypes are readily and comparably assessed in both humans and model organisms and are controlled by well-defined CNS circuits. Discovery of a common gait phenotype between NDDs might suggest shared cellular and molecular deficits and highlight simple outcome variables to potentially quantify longitudinal treatment efficacy in NDDs.

**Methods:** We characterized gait using the DigiGait assay in two different murine NDD models: the complete deletion (CD) mouse, which models hemizygous loss of the complete WS locus, and the *Nf1*<sup>+/<sup>R681X</sup> mouse, which models a NF1 patient-derived heterozygous germline *NF1* mutation. Longitudinal data were collected across four developmental time points (postnatal days 21–30) and one early adulthood time point.</sup>

**Results:** Compared to wildtype littermate controls, both models displayed markedly similar spatial, temporal, and postural gait abnormalities during development. Developing CD mice also displayed significant decreases in variability metrics. Multiple gait abnormalities observed across development in the *Nf1*<sup>+/<sup>R681X</sup> mice persisted into early adulthood, including increased stride length and decreased stride frequency, while developmental abnormalities in the CD model largely resolved by adulthood.</sup>

**Conclusions:** These findings suggest that the subcomponents of gait affected in NDDs show overlap between disorders as well as some disorder-specific features, which may change over the course of development. Our incorporation of spatial, temporal, and postural gait measures also provides a template for gait characterization in other NDD models and a platform to examining circuits or longitudinal therapeutics.

**Keywords:** Gait, Williams Syndrome, Neurofibromatosis Type 1, mice, precision medicine, neurodevelopmental disorders

\* Correspondence: [maloneys@wustl.edu](mailto:maloneys@wustl.edu)

†Joseph D. Dougherty and Susan E. Maloney contributed equally to this work.

<sup>2</sup>Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA

<sup>4</sup>Intellectual and Developmental Disabilities Research Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Despite a growing understanding of the clinical deficits that characterize neurodevelopmental disorders (NDDs), motor impairments remain an understudied yet prevalent phenotype across many NDDs. Motor phenotypes such as abnormal gait are a well-documented feature pervasive in NDDs [1–5] and represent a brain function and circuit better understood and more highly conserved across humans and mice than that of the social and cognitive phenotypes also characteristic to NDDs. Thus, they represent an opportunity to define the consequences of NDD-associated genetic mutations on the development and function of well-understood CNS circuits, and to determine whether distinct neurogenetic disorders might have some shared consequences. Furthermore, these more accessible phenotypes could be used to judge both the efficacy of NDD treatments as well as the effect of long-term use of these therapeutics. However, the existence of a common gait phenotype between multiple NDDs has not been established. This is due to the difficulty of performing longitudinal human studies and the confounding effects of genetic heterogeneity in clinical populations.

Williams Syndrome (WS) and Neurofibromatosis Type 1 (NF1) are two NDDs with known gait disruptions and well-understood genetic etiologies, making them ideal options for a focused examination of a subsection of the heterogeneous NDD clinical population. Gait abnormalities in WS are known to occur during childhood and persist into adulthood [2, 6]. NF1 gait phenotypes have also been reported during childhood and adolescence [7], but their trajectory into adulthood is less well-documented. In addition, gait abnormalities are among the motor phenotypes observed in approximately 80% of autism spectrum disorder (ASD) cases [1], and almost half of all NF1 patients exhibit at least partial ASD symptomatology [8, 9]. Specifically, about 25% of NF1 patients exhibit a phenotypic profile consistent with idiopathic ASD, and another 20% exhibit partial ASD symptomatology [8, 9]. Recently, the *NF1* gene was confirmed as a quantitative trait loci for ASD [9]. This large-scale study identified that the Quantitative Autistic Trait (QAT) scores for NF1 individuals were continuously distributed and pathologically shifted. Whether these NF1 gait phenotypes are a result of ASD overlap or are an independent feature of NF1 has yet to be determined.

Mouse models provide an excellent opportunity to directly target the specific effects of genotype on phenotype in NDDs and to map the neural circuitry underlying abnormalities in these conditions. Production of complex motor behavior, such as gait, is a conserved behavior and robustly studied in mice and humans. Besides allowing for the study of targeted alleles and providing brain

samples to understand cellular and molecular consequences, mouse models also permit longitudinal studies to be performed in a much shorter timeframe than in humans, so that subtle changes in developmental trajectories across the population can be investigated. Crucially, studying multiple mouse models of NDD permits the execution of well-powered studies capable of identifying phenotypes too subtle to detect in clinical study populations, as well as the investigation of commonalities across models.

For these reasons, we characterized gait during development and in adulthood in mouse models of WS and NF1 in order to determine whether developmental gait abnormalities in these NDDs resolve or persist into adulthood. Using our recently developed DigiGait pipeline [10], we quantified gait in the complete deletion (CD) mouse model hemizygous for the 26-gene WS locus [11] and a mouse model harboring a patient-derived heterozygous loss-of-function missense mutation in the *Nf1* gene (*Nf1*<sup>+/*R681X*</sup>). This mutation was chosen, as it has been reported in numerous individuals with NF1 [12–14], and develops brain and nerve tumors [15–17] similar to those described using an artificial *Nf1* knockout allele [18, 19]. The use of this particular *Nf1* mutant mouse model more accurately represents a precision medicine-based approach to characterizing neurodevelopmental disease. We found that both the CD and *Nf1*<sup>+/*R681X*</sup> models exhibited gait alterations during development relative to WT littermates, many of which persisted into adulthood in the *Nf1*<sup>+/*R681X*</sup> mice but not the CD mice. Unexpectedly, across these two different models of NDD, the abnormalities during development were nearly identical. These results suggest that these NDDs share a common gait phenotype and provide a foundation for the future study of treatments that may rescue motor circuit dysfunction in these models.

## Methods

### Animals

All experimental protocols were approved by and performed in accordance with the relevant guidelines and regulations of the Institutional Animal Care and Use Committee of Washington University in St. Louis and were in compliance with US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals. All mice (*Mus musculus*) used in this study were maintained and bred in the vivarium at Washington University in St. Louis. The colony room lighting was a 12:12-h light/dark cycle, with room temperature (~ 20–22 °C) and relative humidity (50%) controlled automatically. Standard lab diet and water were freely available. Pregnant dams were individually

housed in translucent plastic cages measuring 28.5 × 17.5 × 12 cm with corncob bedding. Upon weaning at postnatal day (P)21, mice for behavioral testing were group-housed according to sex.

Gait was assessed in two mouse lines modeling genetic risk for the neurodevelopmental disorders Neurofibromatosis Type 1 (NF1) and Williams Syndrome (WS). The NF1 model harbored a NF1-patient-derived *Nf1* gene mutation (c.2041C>T;p.R681X; *Nf1*<sup>+/<sup>R681X</sup>) [16]. To generate this cohort, *Nf1*<sup>+/<sup>R681X</sup> mice were crossed to C57BL/6J wildtype (WT; RRID:IMSR\_JAX:000664) mice to produce 30 *Nf1*<sup>+/<sup>R681X</sup> (14 males, 16 females) and 40 WT (24 males, 16 females) littermates. Homozygous *Nf1* deletion is embryonic lethal and not found in patients with NF1 [20] and thus was not modeled here. The WS model harbors a heterozygous complete deletion (CD) of the WS critical region comprising 26 genes on the conserved syntenic region of chromosome 5 in the mouse [11]. This cohort was generated by crossing CD mice to WT mice to generate 24 CD (9 males, 15 females) and 44 WT (19 males, 25 females) littermates. Homozygous deletion of the WS critical region also is embryonic lethal.</sup></sup></sup>

#### Gait analysis

Gait data was collected using the DigiGait Imaging System (Mouse Specifics, Inc.; Framingham, MA), an advanced gait analysis system with Ventral Plane Imaging Technology that generates digital paw prints from the animal as it runs on a motorized treadmill [21]. All behavioral experiments were performed by a female experimenter blinded to genotype. All behavioral testing occurred during the light phase between 12:00pm and 6:00pm. Gait performance was collected four times across development and again during adulthood (Fig. 1a) as previously described [10]. These developmental ages were chosen based on our previous work characterizing gait development in the mouse. Briefly, mice were habituated to the apparatus environment and belt movement at P20. Gait testing occurred at P21, P24, P27, P30, and once again after P60. On each test day, a video was captured of each animal's gait at an age-appropriate belt speed (20 cm/s during development and 30 cm/s in adulthood). Gait video processing and metric selection, as well as body length quantification, were conducted as previously described [10]. Body length was measured due to our previous findings that body length influences mouse gait metrics [10]. Please see [10] for a characterization of body length's relationship with these gait metrics.

#### Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics software (v.25, RRID:SCR\_002865). Prior to


analyses, all data were screened for missing values, fit of distributions with assumptions underlying univariate analyses, and influential outliers. Hierarchical linear mixed modeling was used to analyze gait data across juvenile ages, with genotype, sex, and age as fixed effects. Age was also used as a repeated random factor clustered by subject ID. Body length was added as a covariate to account for the influence on gait of changing body length across development. Adult data was analyzed using a two-way ANCOVA, with genotype and sex as fixed effects and body length as a covariate. The Benjamini-Hochberg correction for false discovery rate (FDR; at  $q = .1$ ) was used to adjust the critical alpha level for multiple analyses within each mouse line. A fixed effect of sex was not observed in any gait parameter in either model reported here, except for stance width variability during development in *Nf1*<sup>+/<sup>R681X</sup> males. Therefore, all data below, except for *Nf1*<sup>+/<sup>R681X</sup> forelimb stance width variability, is collapsed across sex. The datasets generated and analyzed in this study are available from the corresponding author upon reasonable request.</sup></sup>

#### Results

Cross-sectional studies of gait in NDD models reveal disorder symptomatology at a particular point in time, yet they cannot determine whether gait abnormalities reflect a delay in typical development or a persistent abnormality. Resolution of gait defects by adulthood would suggest developmental delay, while persistence in adulthood would reflect a more permanent phenotype. Therefore, we used a longitudinal design to quantify gait across development and in adulthood to parse resolution versus persistence of gait phenotypes in *Nf1*<sup>+/<sup>R681X</sup> and WS mouse models, as well as characterize a comprehensive set of spatial, temporal, and postural gait subcomponents and identify those most affected in these NDDs.</sup>

#### Trajectory of gait development over time replicates previous findings independent of genotype

Previous studies have identified multiple spatial, temporal, and postural characteristics of gait that vary across development in the C57BL/6J background strain used here [10]. When collapsed across genotype, both models in the present study largely replicated this previous work; no significant age by genotype interactions were observed. As previously reported, spatial subcomponents such as stance width, excepting the *Nf1*<sup>+/<sup>R681X</sup> hindlimb measure, varied significantly across age when compared to WT littermates in both the *Nf1*<sup>+/<sup>R681X</sup> and CD mice. Temporal variables such as swing and stance duration in both fore- and hindlimbs and hindlimb propulsion duration also changed in our models across age as in the previous study, as well as postural elements such as peak</sup></sup>



paw area and maximum rate of paw contact change of the hindpaws (Table 1) [10]. Some additional age-dependent effects independent of genotype not previously reported, such as changes in stride frequency, were also observed. Overall, these findings confirmed that the progression of baseline, healthy gait development across age in our controls aligned with the age-dependent gait changes previously reported and confirmed that our

genotype-dependent findings were based in disease-related dysfunction.

**Both *Nf1*<sup>+/R681X</sup> and CD models display abnormal spatial, temporal, and postural gait characteristics in development**

Consistent with NDD risk factors disrupting gross motor development, both *Nf1*<sup>+/R681X</sup> and CD models displayed

**Table 1** Summary of significant findings for juvenile mice and adult mice across both *Nf1* and CD models

GAIT PARAMETER	LIMB	CD DEVELOPMENT	CD ADULT	<i>Nf1</i> DEVELOPMENT	<i>Nf1</i> ADULT
<b>Spatial Subcomponent</b>					
Stride Frequency	Fore	A, <b>G ↓</b>	-	A, <b>G ↓</b>	G ↓
	Hind	A, <b>G ↓</b>	-	A, <b>G ↓</b>	G ↓
Stride Length	Fore	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
	Hind	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
Stance Width	Fore	A	-	A	-
	Hind	A, <b>G ↓</b>	-	G ↑	-
Paw Overlap Distance	Hind	A, <b>G ↑</b>	-	G ↓	-
Paw Placement Positioning	Hind	G ↓	-	-	-
Gait Symmetry		-	-	A	-
<b>Temporal Subcomponent</b>					
Swing Duration	Fore	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
	Hind	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
Stance Duration	Fore	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
	Hind	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
Brake Duration	Fore	<b>G ↑</b>	-	A, <b>G ↑</b>	-
	Hind	-	-	-	-
Propulsion Duration	Fore	G ↑	-	-	G ↑
	Hind	A, <b>G ↑</b>	-	A, <b>G ↑</b>	G ↑
Stance Factor	Fore	-	-	-	-
	Hind	-	-	-	-
Max Rate Paw Contact Change	Fore	A, <b>G ↓</b>	-	A	-
	Hind	A, <b>G ↓</b>	-	A, <b>G ↓</b>	-
% Stance	Fore	-	G ↓	A, <b>G ↓</b>	-
	Hind	<b>G ↓</b>	-	A, <b>G ↓</b>	-
% Swing	Fore	-	G ↑	A, <b>G ↑</b>	-
	Hind	<b>G ↑</b>	-	A, <b>G ↑</b>	-
% Shared Stance	Hind	<b>G ↓</b>	-	<b>G ↓</b>	-
<b>Postural Subcomponent</b>					
Absolute Paw Angle	Fore	A, <b>G ↑</b>	-	A, <b>G ↓</b>	-
	Hind	A	-	A, <b>G ↑</b>	-
Step Angle	Fore	-	-	-	-
	Hind	<b>G ↑</b>	-	<b>G ↑</b>	-
Peak Paw Area	Fore	G ↓	-	A	-
	Hind	A, <b>G ↓</b>	-	A	-
<b>Intra-individual Variability Parameters</b>					
Stride Length CV	Fore	G ↓	-	-	-
	Hind	G ↓	-	-	-
Stance Width CV	Fore	G ↓	-	-	-
	Hind	G ↓	-	-	-
Swing Duration CV	Fore	G ↓	-	-	-
	Hind	G ↓	-	-	-
Paw Angle CV	Fore	G ↓	-	A	-
	Hind	G ↓	-	-	-
Step Angle CV	Fore	-	-	-	-
	Hind	G ↓	-	-	-
Peak Paw Area CV	Fore	-	-	A	-
	Hind	A, <b>G ↓</b>	-	A	-

For each gait parameter, main effects of age (A) and genotype (G) are indicated where significant after FDR correction. Genotype effects shared across models are in bold. Age by genotype interactions were also explored but none survived correction. Arrows indicate the direction of the genotype effect regarding Het compared to WT (down arrows indicate lower score for Het compared to WT; up arrows indicate higher score for Het compared to WT). *N* = 24 Het CD mice and 44 WT CD mice; *N* = 30 Het *Nf1*<sup>+/*R681X*</sup> mice and 40 WT *Nf1*<sup>+/*R681X*</sup> mice

significant differences compared to WT littermate controls in multiple spatial, temporal, and postural subcomponents of gait during development (Table 1). Stride length, an important spatial gait subcomponent, was significantly increased in both models as compared to their WT littermate controls (Fig. 1b, c). Correspondingly, stride frequency was significantly decreased in both CD mice and *Nf1*<sup>+/*R681X*</sup> mice relative to controls (Fig. 1d, e). Spatial gait abnormalities in stance width and overlap distance were also observed in both models, with a narrower hindlimb stance width for CD mice than controls and a wider hindlimb stance width in *Nf1*<sup>+/*R681X*</sup> mice (Fig. 1f, g). There was also an increased overlap distance in CD mice, which was decreased in *Nf1*<sup>+/*R681X*</sup> mice compared to controls (Fig. 1h, i). The only gait component that displayed a sex effect in either model was *Nf1*<sup>+/*R681X*</sup> forelimb stance width coefficient of variance (CV), a measure of relative variability (females 14.562 ± .417, males 13.278 ± .385), but an interaction between sex and genotype was not a predictor of outcome. Furthermore, genotype was not a significant predictor of forelimb stance width CV for either females or males when analyzed separately. In addition, hindpaw placement positioning was significantly reduced in the CD but not *Nf1*<sup>+/*R681X*</sup> mice as compared to WT littermates (Fig. 1j, k), suggesting that spatial gait abnormalities are not entirely identical between these two NDD models despite their remarkable similarities.

In terms of temporal subcomponents of the gait phenotype, both CD and *Nf1*<sup>+/*R681X*</sup> models displayed significant changes in swing duration and other related metrics as compared to WT littermates. In both fore- and hindlimbs, swing duration was significantly increased in developing CD mice and *Nf1*<sup>+/*R681X*</sup> mice when compared to WT controls (Fig. 2a, b). The percentage of the total stride cycle that was spent in the stance phase was significantly decreased in CD hindlimbs as well as both *Nf1*<sup>+/*R681X*</sup> fore- and hindlimbs, while propulsion duration was longer in CD fore- and hindlimbs and *Nf1*<sup>+/*R681X*</sup> hindlimbs compared to WT littermates (Fig. 2c–f).


In addition to spatial and temporal characteristics of gait, postural differences in both NDD models were evident when compared to controls. The absolute angle of the forepaws was significantly increased in both CD and *Nf1*<sup>+/*R681X*</sup> models (Fig. 3a, b), suggesting that these animals show an altered body positioning while walking. While *Nf1*<sup>+/*R681X*</sup> mice did not display any other significant abnormalities in postural gait metrics, CD animals showed a significant reduction in peak paw area on the walking surface for both fore- and hindpaws (Fig. 3c, d). These findings suggest that posture while walking is significantly impacted in development in both the *Nf1*<sup>+/*R681X*</sup> and CD models.

### Gait abnormalities persist into early adulthood for *Nf1*<sup>+/*R681X*</sup> mice but largely resolve for CD mice

We have thus far reported our characterization of developmental gait abnormalities in both the CD and *Nf1*<sup>+/*R681X*</sup> models. We also quantified gait in these models in adulthood to investigate whether these phenotypes reflect a developmental delay in gait and resolution by adulthood or reflect a permanent abnormality and persistence into adulthood. In contrast to the multiple spatial, temporal, and postural abnormalities in development, adult CD mice only displayed one significant difference compared to WT littermates, a decrease in the percentage of the forelimb stride cycle spent in the stance phase and an accompanying increase in the percentage spent in swing (Fig. 4a–f). While temporal stance and swing abnormalities were also present in CD mice during development, their decreased stance phase percentage was observed in the hindlimbs, not forelimbs, and therefore, the temporal stride cycle phenotype observed in adulthood does not appear to have directly persisted from the developmental period (Table 1). Conversely, *Nf1*<sup>+/*R681X*</sup> mice displayed numerous phenotypes that persisted from development into adulthood, including significantly increased stride length and decreased stride frequency, as well as longer stance, swing, and propulsion durations in both fore- and hindlimbs relative to WT littermates (Fig. 4g–l). Although approximately half of the gait metrics perturbed in developing *Nf1*<sup>+/*R681X*</sup> mice no longer showed significant differences in adulthood, developmental and adult *Nf1*<sup>+/*R681X*</sup> datasets displayed a high degree of concordance in the direction of effect for the gait alterations that remained present in adulthood. The perturbed gait variables in *Nf1*<sup>+/*R681X*</sup> adults also tended to be the most highly significant variables during development, such as stride length, which was significantly increased in both development and adulthood as compared to WT littermates (Fig. 5). Overall, these findings demonstrate that *Nf1*<sup>+/*R681X*</sup> mice exhibited multiple spatial, temporal, and postural gait abnormalities in gait subcomponents that persist into adulthood, while the CD model had developmental disruptions in gait that were largely resolved by adulthood.


### Reduced intraindividual gait variability is evident in CD but not *Nf1*<sup>+/*R681X*</sup> mice in development but resolves by adulthood

In both clinical populations as well as mouse models of NDD, a compelling question regarding development remains whether individuals show significant variability in their own gait or other symptomatology. For typically developing children, gait variability decreases across development as children become more proficient at walking and take more consistent steps [22]. However,



children with NDDs often exhibit greater gait variability, including increased variability in stride length and other metrics in children with ASD [23, 24]. Adults with WS also show increased intraindividual variability in stride length and other measures [2]. When comparing intraindividual variability of *Nf1*<sup>+/R681X</sup> animals and WT littermates, no significant differences were observed, but CD mice did significantly differ in their variability of several

gait metrics compared to their WT littermates. Specifically, variability in multiple gait measures that included stride length, stance width, and swing duration were all reduced in developing CD mice compared to WT littermates (Fig. 6, Table 1). This reduced variability did not persist into adulthood, as no gait metrics displayed significant differences in variability for adult CD mice relative to WT littermates (Table 1). This implies that the




reduced gait variability observed in the CD model occurred only during development and resolved by adulthood.

**Discussion**

Through characterization of gait during development and adulthood in mouse models of WS and NF1, we identified, for the first time, aspects of gait perturbed by these specific genetic NDD liabilities in a model system. Furthermore, we sought to determine whether developmental gait abnormalities in these NDDs resolve by adulthood and would therefore represent a delay in gait development, rather than a persistent abnormality. Our findings indicated that the *Nf1*<sup>+/R681X</sup> mouse, which models a patient-derived mutation, and the CD mouse, which models hemizygous loss of the complete WS locus, both exhibit abnormalities in multiple features of gait that are evident during development. These features included an increase in stride length, propulsion duration, and swing duration as well as a decrease in stride frequency for both models as compared to controls. These abnormalities persisted into adulthood in the *Nf1*<sup>+/R681X</sup> model of NF1 but largely resolved in the CD model of WS, which displayed only one significant adult phenotype, a decreased percentage of the forelimb stride cycle spent in the stance phase compared to controls. The differences observed in spatial, temporal, and postural subcomponents of gait in both developing and adult *Nf1*<sup>+/R681X</sup> animals suggest their gait abnormalities

persist, while CD deficits largely disappeared by very early adulthood, with only select stride cycle features perturbed at this age. The CD model also displayed reduced intraindividual variability for several gait metrics during development, a feature that did not appear in adulthood or in the *Nf1*<sup>+/R681X</sup> mice, suggesting this variability phenotype may be specific to the developing WS model and not necessarily to NDDs in general. Overall, the considerable overlap in abnormalities between these WS and NF1 models suggests that NDDs have multiple common gait phenotypes but may differ in their time course, with some abnormalities persisting into adulthood, while others reflect a developmental delay that eventually resolves.

Although the percentage of the stride cycle represented by swing or stance phases was the only metric significantly different from controls in the adult CD mice, several of the gait metrics perturbed during development have previously been reported to be altered in adult WS patient populations. While we observed significantly reduced intraindividual variability for several gait features in developing CD mice, increased gait variability has previously been documented in adults with WS, specifically for stride length and stance time as a percentage of the total gait cycle [2]. Stride length and hindlimb stance width were both altered in CD development, but while the mice showed increased stride length and reduced stance width, Hocking et al. [2] reported that adults with WS exhibited reduced stride length and




an increased base of support, equivalent to stance width [25]. This discrepancy in direction of effect may be attributable to the fact that our analysis focused on gait change independent of body size differences by using the body length adjustment we included in our statistical model, which was not accounted for in the human study, or the fact that their assay recorded gait at a self-determined speed instead of a forced speed like DigiGait. Although our study focuses on developmental changes in gait, age differences likely also play a role in adults, given the significant evolution of gait across time. Adult CD mice no longer showed the stride length and stance width abnormalities present in development, so it is possible that characterization of gait in older CD adults might reveal a continued trend of decreasing stride length and increasing stance width. Despite this apparent difference in direction of effect, the fact that similar gait metrics showed alterations in both human and mouse studies is interesting and should be explored in future studies, particularly with older mouse models and child and adolescent WS populations.

These data provide a foundation for investigating which genes in the WS critical region, in isolation or in

combination, may be driving the gait abnormalities observed here. The transcription factors *Gtf2i* and *Gtf2ird1*, for instance, have been ruled out for most other WS neurobehavioral phenotypes [26, 27], but may still be involved in the motor dysfunction. Future studies involving intercrossing of mutants harboring loss of function mutations in single WS genes will help to clarify the role of each of the WS locus genes in gait function.

The developmental gait differences between *Nf1*<sup>+/R681X</sup> mice and controls also relate to findings previously reported in the human NF1 literature. The significantly increased stride length that we observed in developing *Nf1*<sup>+/R681X</sup> mice, although not in the same direction of effect, relates to a previous study of children with NF1 which showed significantly decreased stride length [7]. The increase in hindlimb stance width compared to controls that we observed across development in *Nf1*<sup>+/R681X</sup> mice also differs from the decreased base of support reported in NF1 children compared to reference values. However, as noted above, these human studies did not employ a treadmill-based assay nor account for body size, both of which are known to affect numerous gait




metrics [10, 28]. Additional data collection in NF1 patient populations that standardizes walking speed by utilizing a treadmill or similar device will allow for more meaningful comparison to our DigiGait forced-gait findings. Because few human NF1 gait studies have been performed, collection of more data across the lifespan should elucidate whether the spatial, temporal, and postural gait phenotypes we observed in *Nf1*<sup>+/R681X</sup> mice reflect a similarly persistent phenotype in the patient population.

Crucially, the use of a patient-derived mutation in our *Nf1* model represents an increasingly feasible precision medicine approach to disease modeling, setting an example for how mouse models can be used in future studies of NDD mechanisms and interventions. There are multiple other genetically engineered mouse models of *Nf1* mutations, both artificial [18, 19, 29, 30] and patient-derived mutations [15–17], which can be similarly assessed for gait function and compared to the present findings. Identification of the similarities and differences in gait phenotype across different *Nf1* precision mutation models [16, 17, 31] will facilitate the identification of *NF1* mutation-specific effects and the discovery of successful interventions for the various motor deficits seen in patients with NF1. In addition, we can use these patient-derived models to parse genotype-phenotype relationships in gait function as has been identified for other NF1 phenotypes such as optic glioma presentation and ASD features [32, 33].

The presence of gait abnormalities and the persistence of some into adulthood are also consistent with studies of other NDD mouse models. The *Mecp2* mouse model of Rett syndrome displayed a reduced stride length in adulthood [34], one of the gait metrics we observed to be perturbed in both CD and *Nf1*<sup>+/R681X</sup> models.

Similarly, the valproic acid mouse model of ASD has previously been reported to exhibit a decreased stride length in the juvenile period compared to controls [35]. Although this direction of effect is opposite the increased stride length we observed in both CD and *Nf1*<sup>+/R681X</sup> developing mice, a correction for body length, such as we performed, might reveal greater similarity across models. Alternatively, the developmental trajectory of gait differences that we observed in *Nf1*<sup>+/R681X</sup> mice may vary in timing between models, with some showing more prolonged developmental delays than others. While some metrics such as stride length are consistently characterized across NDD gait studies, inclusion of the other variables examined here varies greatly between studies. A standard and comprehensive list of gait metrics to include in future studies would also benefit the field greatly by allowing more between-model comparisons.

Several limitations of rodent model gait analysis should be noted and provoke further studies of NDD-related gait phenotypes. Mice are quadrupeds instead of bipeds, and therefore, extrapolation of mouse model gait results to human populations must be done cautiously. However, in our previous study of wildtype mice, we documented gait differences across time that mirrored those previously observed in human gait development [10], and therefore, we feel that the present study also provides meaningful information about the influence of WS locus hemizyosity and *Nf1* mutation on gait neurocircuit function. A substantial advantage of the DigiGait system is that it allows standardization of gait speed across mice, which is important because speed significantly contributes to gait variability [36, 37]; however, assays of spontaneous gait such as the CatWalk (Noldus)



**Fig. 6** Magnitude of CD developmental gait variability metrics is significantly smaller than controls. Change in CD forelimb and hindlimb coefficient of variance (CV) metrics of **a** stride length, **b** stance width, **c** swing duration, **d** step angle, **e** peak paw area, and **f** paw angle at P21, P24, P27, and P30 (purple = het,  $N = 24$ ; green = WT,  $N = 44$ ). Data are means  $\pm$  SEM. Asterisk indicates significance after FDR correction. Hindlimb means are represented by squares, and forelimb means are represented by circles

may allow for parsing of additional gait differences that reflect motivation-related behavior.

The gait phenotypes we have described here provide the basis for numerous future studies of NDD behavioral trajectories and suggest a potential outcome variable in the testing of NDD treatments. The concordance between gait phenotypes in our two NDD models is striking and unusual, as the establishment of phenotypes common to multiple NDDs has traditionally been a major challenge in the field when assessing more cognitive behaviors in rodent models. We have reported here a common signature between two NDDs in gait, a behavioral measure that is accessible and linked to a relatively well-understood circuit, and this methodology can be easily applied to other NDD mouse models to assess whether the observed gait abnormalities apply to a larger number of NDD liabilities. If the gait phenotype observed here is common to other NDDs, that would suggest that this phenotype, even though not as central to

the human definition of NDDs, might be a very sensitive and consistent gauge to assess what an NDD mutation does to a functioning CNS circuit. Investigating the related cellular and molecular consequences is also facilitated by the deep understanding of motor circuitry relative to the more abstract circuitry characteristic of other NDD cognitive phenotypes. Finally, regardless of the presence or absence of commonalities, within a given NDD, gait could be widely used to test treatments across development, measure normalization of circuit function, and assess the effect of long-term therapies.

## Conclusions

We found that both the CD model of Williams Syndrome and the *Nf1*<sup>+/<sup>R681X</sup> model of a patient-derived *NF1* mutation shared multiple spatial, temporal, and postural developmental gait abnormalities. Overall, our findings indicate that NDDs may share features of atypical gait, yet differ in resolution or persistence of these</sup>

phenotypes. Therefore, gait may serve as a useful outcome variable in studies of therapeutics' efficacy in the long-term treatment of NDD.

#### Abbreviations

NDD: Neurodevelopmental disorder; WS: Williams Syndrome; NF1: Neurofibromatosis Type 1; CD: Complete deletion; ASD: Autism spectrum disorder

#### Acknowledgements

The authors thank the Co-Directors of the Animal Behavior Core at Washington University School of Medicine, Carla Yuede, PhD, and David Wozniak, PhD, for the access to the DigiGait equipment.

#### Authors' contributions

RMR wrote the manuscript. CTW collected the data, performed husbandry, and performed preliminary analysis. DHG developed and provided reagents (mice). JDD and SEM designed the study and developed the methodology. SEM also analyzed the data and wrote the manuscript. All authors read, edited, and approved the final manuscript.

#### Funding

Support for this study was provided by the NIMH (R01MH107515, JDD), NINDS (F31NS110222, RMR; R35NS097211, DHG), and NICHD (P50HD103525, Intellectual and Developmental Disabilities Research Center at Washington University).

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

#### Declarations

##### Ethics approval and consent to participate

All experimental protocols were approved by and performed in accordance with the relevant guidelines and regulations of the Institutional Animal Care and Use Committee of Washington University in St. Louis, and were in compliance with US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.

##### Consent for publication

Not applicable

##### Competing interests

The authors declare that they have no competing interests.

##### Author details

<sup>1</sup>Department of Genetics, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA. <sup>2</sup>Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA. <sup>3</sup>Department of Radiology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA. <sup>4</sup>Intellectual and Developmental Disabilities Research Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA. <sup>5</sup>Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA.

Received: 27 October 2020 Accepted: 5 March 2021

Published online: 20 March 2021

#### References

- Hilton CL, Zhang Y, Whilte MR, Klohr CL, Constantino J. Motor impairment in sibling pairs concordant and discordant for autism spectrum disorders. *Autism*. 2012;16(4):430–41. <https://doi.org/10.1177/1362361311423018>.
- Hocking DR, Rinehart NJ, McGinley JL, Bradshaw JL. Gait function in adults with Williams syndrome. *Exp Brain Res*. 2009;192(4):695–702. <https://doi.org/10.1007/s00221-008-1586-3>.
- Kindregan D, Gallagher L, Gormley J. Gait Deviations in children with autism spectrum disorders: a review. *Autism Res Treat*. 2015;2015:1–8. <https://doi.org/10.1155/2015/741480>.
- Kraan CM, Tan AHJ, Cornish KM. The developmental dynamics of gait maturation with a focus on spatiotemporal measures. *Gait Posture*. 2017;51:208–17. <https://doi.org/10.1016/j.gaitpost.2016.10.021>.
- Sanders RD, Gillig PM. Gait and Its assessment in psychiatry. *Psychiatry Edgemont*. 2010;7(7):38–43.
- Morris CA, Braddock SR, Council on Genetics. Health care supervision for children with Williams syndrome. *Pediatrics*. 2020;145(2):e20193761.
- Champion JA, Rose KJ, Payne JM, Burns J, North KN. Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. *Dev Med Child Neurol*. 2014;56(5):468–74. <https://doi.org/10.1111/dmcn.12361>.
- Garg S, Green J, Leadbitter K, Emsley R, Lehtonen A, Evans DG, Huson SM. Neurofibromatosis type 1 and autism spectrum disorder. *Pediatrics*. 2013;132(6):e1642–8. <https://doi.org/10.1542/peds.2013-1868>.
- Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN. Disease burden and symptom structure of autism in neurofibromatosis type 1: a study of the International NF1-ASD Consortium Team (INFACT). *JAMA Psychiatry*. 2016;73(12):1276–84. <https://doi.org/10.1001/jamapsychiatry.2016.2600>.
- Akula SK, McCullough KB, Weichselbaum C, Dougherty JD, Maloney SE. The trajectory of gait development in mice. *Brain Behav*. 2020;10(6):e01636.
- Segura-Puimedon M, Sahún I, Velot E, Dubus P, Borralleras C, Rodrigues AJ, Valero MC, Valverde O, Sousa N, Herault Y, Dierssen M, Pérez-Jurado LA, Campuzano V. Heterozygous deletion of the Williams–Beuren syndrome critical interval in mice recapitulates most features of the human disorder. *Hum Mol Genet*. 2014;23(24):6481–94. <https://doi.org/10.1093/hmg/ddu368>.
- Kocova M, Kochova E, Sukarova-Angelovska E. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature. *BMC Endocr Disord*. 2015;15(1):82. <https://doi.org/10.1186/s12902-015-0076-4>.
- Messiaen L, Wimmer K. In: Kaufmann D, editor. NF1 mutational spectrum. In: *Monographs in human genetics: neurofibromatosis*. Basel: Karger; 2008. p. 63–77.
- Wang Q, Pierce-Hoffman E, Cummings BB, Alfoldi J, Francioli LC, Gauthier LD, et al. Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes. *Nat Commun*. 2020;11(1):2539. <https://doi.org/10.1038/s41467-019-12438-5>.
- Li K, Turner AN, Chen M, Brosius SN, Schoeb TR, Messiaen LM, Bedwell DM, Zinn KR, Anastasaki C, Gutmann DH, Korf BR, Kesterson RA. Mice with missense and nonsense *NF1* mutations display divergent phenotypes compared with human neurofibromatosis type I. *Dis Model Mech*. 2016;9(7):759–67. <https://doi.org/10.1242/dmm.025783>.
- Toonen JA, Anastasaki C, Smithson LJ, Gianino SM, Li K, Kesterson RA, Gutmann DH. *NF1* germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. *Hum Mol Genet*. 2016;25(9):1703–13. <https://doi.org/10.1093/hmg/ddw039>.
- Guo X, Pan Y, Gutmann DH. Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. *Neuro-Oncol*. 2019;21(10):1250–62. <https://doi.org/10.1093/neuonc/noz080>.
- Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. *Genes Dev*. 1994;8(9):1019–29. <https://doi.org/10.1101/gad.8.9.1019>.
- Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in *Nf1*. *Nat Genet*. 1994;7(3):353–61. <https://doi.org/10.1038/ng0794-353>.
- Gutmann DH, Giovannini M. Mouse models of neurofibromatosis 1 and 2. *Neoplasia*. 2002;4(4):279–90. <https://doi.org/10.1038/sj.neo.7900249>.
- Hampton T, Stasko M, Kale A, Amende I, Costa A. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. *Physiol Behav*. 2004;82(2–3):381–9. <https://doi.org/10.1016/j.physbeh.2004.04.006>.
- Hausdorff JM, Zeman L, Peng C-K, Goldberger AL. Maturation of gait dynamics: stride-to-stride variability and its temporal organization in children. *J Appl Physiol*. 1999;86(3):1040–7. <https://doi.org/10.1152/jappl.1999.86.3.1040>.

23. Nayate A, Tonge BJ, Bradshaw JL, McGinley JL, Iansek R, Rinehart NJ. Differentiation of high-functioning autism and Asperger's disorder based on neuromotor behaviour. *J Autism Dev Disord*. 2012;42(5):707–17. <https://doi.org/10.1007/s10803-011-1299-5>.
24. Rinehart NJ, Tonge BJ, Bradshaw JL, Iansek R, Enticott PG, McGinley J. Gait function in high-functioning autism and Asperger's disorder: evidence for basal-ganglia and cerebellar involvement? *Eur Child Adolesc Psychiatry*. 2006;15(5):256–64. <https://doi.org/10.1007/s00787-006-0530-y>.
25. Krebs DE, Goldvasser D, Lockert JD, Portney LG, Gill-Body KM. Is base of support greater in unsteady gait? *Phys Ther*. 2002;82(2):138–47. <https://doi.org/10.1093/ptj/82.2.138>.
26. Kopp N, McCullough K, Maloney SE, Dougherty JD. Gtf2i and Gtf2ird1 mutation do not account for the full phenotypic effect of the Williams syndrome critical region in mouse models. *Hum Mol Genet*. 2019;28(20):3443–65. <https://doi.org/10.1093/hmg/ddz176>.
27. Kopp ND, Nygaard KR, Liu Y, McCullough KB, Maloney SE, Gabel HW, et al. Functions of Gtf2i and Gtf2ird1 in the developing brain: transcription, DNA binding and long-term behavioral consequences. *Hum Mol Genet*. 2020; 29(9):1498–519. <https://doi.org/10.1093/hmg/ddaa070>.
28. Herbin M, Hackert R, Gasc J-P, Renous S. Gait parameters of treadmill versus overground locomotion in mouse. *Behav Brain Res*. 2007;181(2):173–9. <https://doi.org/10.1016/j.bbr.2007.04.001>.
29. Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD. Characterization of early communicative behavior in mouse models of neurofibromatosis type 1: early communicative behavior in NF1 models. *Autism Res*. 2018;11(1):44–58. <https://doi.org/10.1002/aur.1853>.
30. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. *Nature*. 2002;415(6871):526–30. <https://doi.org/10.1038/nature711>.
31. Brossier NM, Thondapu S, Cobb OM, Dahiya S, Gutmann DH. Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma. *Neuro-Oncol*. 2020;noaa237. <https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaa237/5932401>.
32. Anastasaki C, Morris SM, Gao F, Gutmann DH. Children with 5'-end *NF1* gene mutations are more likely to have glioma. *Neurol Genet*. 2017;3(5):e192. <https://doi.org/10.1212/NXG.0000000000000192>.
33. Morris SM, Gutmann DH. A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. *Neurology*. 2018;90(8):377–9. <https://doi.org/10.1212/WNL.00000000000005000>.
34. Vogel Ciernia A, Pride MC, Durbin-Johnson B, Noronha A, Chang A, Yasui DH, Crawley JN, LaSalle JM. Early motor phenotype detection in a female mouse model of Rett syndrome is improved by cross-fostering. *Hum Mol Genet*. 2017;26(10):1839–54. <https://doi.org/10.1093/hmg/ddx087>.
35. Al Sagheer T, Haida O, Balbous A, Francheteau M, Matas E, Fernagut P-O, et al. Motor impairments correlate with social deficits and restricted neuronal loss in an environmental model of autism. *Int J Neuropsychopharmacol*. 2018;21(9):871–82. <https://doi.org/10.1093/ijnp/pyy043>.
36. Jordan K, Challis JH, Newell KM. Walking speed influences on gait cycle variability. *Gait Posture*. 2007;26(1):128–34. <https://doi.org/10.1016/j.gaitpost.2006.08.010>.
37. Möckel G, Perka C, Labs K, Duda G. The influence of walking speed on kinetic and kinematic parameters in patients with osteoarthritis of the hip using a force-instrumented treadmill and standardised gait speeds. *Arch Orthop Trauma Surg*. 2003;123(6):278–82. <https://doi.org/10.1007/s00402-003-0513-0>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

